A Senate committee aide told Inside Health Policy an agreement has been reached “between relevant parties” to address in separate legislation a controversial provision included in the 2018 Defense authorization bill that raised flags from FDA because it gave the Department of Defense (DOD) additional authority to authorize emergency use of medical products. “An agreement has been reached between the relevant parties to deal with this issue via a separate piece of legislation,” the aide said. At issue is...